Chandra Ivey, MD
Otolaryngology · New York, NYNPI 1841209798
Payments from drug & device makers
Across 73 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$546
- Kaleo, Inc.$206
- Optinose US, Inc.$164
- GSK$108
- Stryker$92
- Pfizer$79
- plus $533 from 15 others
What the payments were for
- Food & beverage$1,728100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 19 | $546 |
| Kaleo, Inc. | 10 | $206 |
| Optinose US, Inc. | 8 | $164 |
| GSK | 5 | $108 |
| Stryker | 3 | $92 |
| Pfizer | 4 | $79 |
| Integra Lifesciences Corporation | 2 | $74 |
| Novartis | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Hikma Pharmaceuticals USA | 2 | $40 |
| Acclarent, Inc | 2 | $39 |
| Alk-abello, Inc | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| CSL Behring | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Neurent Medical Limited | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| 3b Medical, Inc. | 1 | $23 |
| Merck | 1 | $23 |
| Precigen, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $15 |
How this compares
$1,728 in reported general payments places this provider in the 60th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexlansoprazole DrDexlansoprazole | 12 | $6,197 |
| Cevimeline Hcl | 25 | $2,619 |
| Ipratropium Bromide | 76 | $2,508 |
| Azelastine Hcl | 71 | $1,553 |
| Sucralfate | 16 | $1,508 |
| Famotidine | 70 | $1,232 |
| Fluticasone Propionate | 73 | $1,217 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 17 | $732 |
| Methylprednisolone | 67 | $498 |
| Pilocarpine Hcl | 12 | $465 |
| Clotrimazole | 18 | $392 |
| Pantoprazole Sodium | 17 | $383 |
| Amitriptyline Hcl | 13 | $265 |
| Gabapentin | 18 | $249 |
| Omeprazole | 38 | $239 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New York
- Anthony DelsignoreNew York$966K
- Roheen RaithathaNew York$882K
- Dennis KrausNew York$524K
- Ashutosh KackerNew York$387K
- Lawrence LustigNew York$383K
- Brett MilesNew York$368K
- Alfred Marc IloretaNew York$342K
- Hae-Ok KimNew York$104K
- Gregory LevitinNew York$48K
- David KaufmanNew York$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.